RxDoctor Payments DataLook up a doctor →

Victor Araya, MD

Hepatology · Doylestown, PANPI 1285693069

Payments from drug & device makers

$855,593in general payments, 2019–2025

Across 820 payments — averaging $1043.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$471K
  • Madrigal Pharmaceuticals$133K
  • Intercept Pharma Europe Ltd.$110K
  • Gilead$73K
  • Boehringer Ingelheim International GmbH$42K
  • AbbVie$9K
  • plus $18K from 38 others
$1,849in research payments, 2019–2025

Across 2 payments — averaging $924.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Consulting fees$6,6706%
  • Speaking & faculty fees$91,14576%
  • Travel & lodging$10,3359%
  • Food & beverage$11,65810%
  • Education$1590%
  • Gifts$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$298,254
Medicare patients
509
Services billed
8,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid13$231,758
RezdiffraResmetirom16$108,535
CreonLipase/Protease/Amylase30$30,507
VemlidyTenofovir Alafenamide14$28,639
LinzessLinaclotide31$25,392
Ursodiol33$7,045
Ondansetron Hcl30$5,909
Dexlansoprazole DrDexlansoprazole21$5,023
SutabSod Sulf/Pot Chloride/Mag Sulf32$5,015
Pantoprazole Sodium167$1,592
Famotidine129$1,484
Mycophenolate Mofetil19$1,223
Omeprazole144$1,058
Esomeprazole Magnesium50$989
Dicyclomine Hcl40$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$470,592$231,75813 claims
Madrigal PharmaceuticalsRezdiffra$133,259$108,53516 claims
AbbVieCreon, Linzess$8,895$55,89861 claims
GileadVemlidy$72,504$28,63914 claims
Braintree Laboratories, Inc.Sutab$203$5,01532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other hepatology in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →